跳至主要内容
临床试验/EUCTR2012-005214-19-NL
EUCTR2012-005214-19-NL进行中(未招募)1 期

A randomized, double-blind, placebo-controlled trial of golimumab+methotrexate versus methotrexate alone in methotrexate-naïve patients with psoriatic arthritis - An RCT of golimumab+MTX vs MTX alone in MTX-naive PsA

Academic Medical Center, Department of Rheumatology0 个研究点目标入组 60 人开始时间: 2013年6月20日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • - Psoriatic arthritis according to the CASPAR classification
  • - Active disease, minimally 3 swollen and tender joints
  • - 18-70 years
  • - a stable dose of concomitant NSAIDs and/or corticosteroids is allowed. The dose of corticosteroids should not exceed a prednisone equivalent = 10 mg/day and must be stable for at least 4 weeks prior to baseline.
  • - Patients are considered to be in generally good health based upon the result of a medical history, physical examination, laboratory profile, chest X-ray and electrocardiography (ECG).
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 50
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 10

排除标准

  • Methotrexate naive
  • TNF blocker naive
  • Concurrent DMARD use
  • Malignancy <5 years ago
  • no active children wish, pregnancy or breast feeding

研究者

发起方
Academic Medical Center, Department of Rheumatology

相似试验